FDA clears Beleodaq
The FDA approves Spectrum Pharmaceuticals
' ( SPPI +4.9% ) Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL) who have relapsed or who are refractory to previous treatment. This is the third drug the agency has cleared since 2009 for the treatment of PTCL. It ...
Read the rest of this article on SeekingAlpha.com: SA Currents